开发人类胆酶和β-分泌酶的潜在多位抑制剂1:一种计算方法
Deyse B Barbosa1, Mayra R do Bomfim1, Tiago A de Oliveira2
1Laboratório de Modelagem Molecular, Departamento de Saúde, Universidade Estadual de Feira de Santana, Feira de Santana 44036-900, BA, Brazil.
Pharmaceuticals (Basel, Switzerland)
|December 23, 2023
概括
这项研究确定ZINC1733是乙胆酶 (AChE),丁胆酶 (BuChE) 和BACE-1的潜在抑制剂,这些酶是阿尔茨海默病的关键酶. 计划进行进一步的测试,以确认其对神经退行性疾病的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- 阿尔茨海默病 (AD) 是痴呆的主要原因,其特点是慢性神经退行.
- 阿尔茨海默症的发病包括胆固醇和粉样蛋白通路,使它们的关键酶成为治疗的点.
- 同时抑制乙胆酶 (AChE),丁胆酶 (BuChE) 和β-分泌酶1 (BACE-1) 是一个有前途的治疗策略.
研究的目的:
- 确定用于ACHE,BuChE和BACE-1的新型多位抑制剂.
- 利用分子建模和虚拟查来发现阿尔茨海默病的潜在治疗剂.
- 为了找到能够同时抑制胆固醇和粉样蛋白通路中的关键酶的化合物.
主要方法:
- 基于 AChE,BuChE 和 BACE-1 的活性位点的药模拟.
- 使用开发的药模型对分子图书馆进行虚拟选.
- 分子对接模拟以评估与目标酶的结合亲和力.
- 评价物理化学性质,毒理学参数和顶级候选者的商业可用性.
- 分子动力学模拟来分析最有前途的抑制剂-酶复合物的稳定性.
主要成果:
- 制造了一种药模型,其中包括疏水中心,键受体和带正电荷的.
- 十二种化合物表现出足够的对所有三个向酶的对接分数.
- ZINC1733对ACHE,BuChE和BACE-1具有最高的抑制潜力.
- 分子动力学模拟证实了ZINC1733酶系统的稳定性.
结论:
- 在的方法成功地确定ZINC1733作为AChE,BuChE和BACE-1的潜在多目标抑制剂.
- ZINC1733代表了作为阿尔茨海默病治疗剂的进一步研究的有希望的候选人.
- 未来的酶分析是必要的,以实验验证ZINC1733.3的预测抑制活性.
更多相关视频
10:58Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
17.1K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
568
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
568